Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jul 27, 2022Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
Jun 30, 2022BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive FRANKLIN LAKES, N.J., June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...
Jun 28, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today unveiled findings from a survey conducted by The Harris...
May 26, 2022Second Test for the BD COR™ MX to be CE Marked to IVD Directive FRANKLIN LAKES, N.J., May 26, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
May 12, 2022510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
-
May 5, 2022
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline...
Feb 25, 2022FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....
Feb 8, 2022Organizations including Superhuman Use BD Veritor™ At-Home COVID-19 Test with the ReturnSafe Platform to Keep Employees Safe at WorkBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...
-
Feb 3, 2022- Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...
Feb 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...